Article
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2023
Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi J V, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt K D, Lindsay J, Rodig S J, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad M M, Maugeri-Saccà M
Abstract excerpt
BACKGROUND: KEAP1 mutations have been associated with reduced survival in lung adenocarcinoma (LUAD) patients treated with immune checkpoint inhibitors (ICIs), particularly in the presence of STK11/KRAS alterations. We hypothesized that, beyond co-occurring genomic events, clonality prediction may help identify deleterious KEAP1 mutations and their counterparts with retained sensitivity to ICIs. PATIENTS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.